c-Myc-Induced Therapy Resistance in Leukemia: Mechanisms and Emerging Therapeutic Opportunities
Dysregulation of the c-Myc oncogene is a pivotal event in leukemia pathogenesis and therapy resistance. This review synthesizes current evidence, illustrating that c-Myc drives leukemogenesis by enhancing proliferation, inhibiting apoptosis, and upregulating immune checkpoints like PD-L1. Its overexpression is linked to poor treatment outcomes across various leukemia subtypes. Directly targeting c-Myc remains challenging; however, indirect epigenetic modifiers (BET inhibitors), transcriptional disruption (CDK9 inhibitors), and combination therapies emerge as promising strategies to suppress its oncogenic activity and overcome resistance, paving the way for improved clinical management.
Authors
- Hossein Kalarestaghi
- Javad Arabpour (ORCID: https://orcid.org/0000-0002-9968-0231)
- Sahar Sadat Moosavi (ORCID: https://orcid.org/0009-0009-2225-5710)
- Ali Rafat (ORCID: https://orcid.org/0000-0002-5594-2906)
- Zeinab Mazloumi (ORCID: https://orcid.org/0000-0002-2298-0228)
- Reza Nejati (ORCID: https://orcid.org/0000-0002-2188-156X)
- Khadijeh Dizaji Asl (ORCID: https://orcid.org/0000-0003-0920-9583)
- Haniye Yarahmadi
- Hediye Khalkhali
Institutions
- Fox Chase Cancer Center (US)
- Islamic Azad University of Tabriz (IR)
- Tarbiat Modares University (IR)
- Tabriz University of Medical Sciences (IR)
- Kashan University of Medical Sciences (IR)
- Ardabil University of Medical Sciences (IR)
- Temple University Health System (US)
Publication Details
- Journal
- Medical Sciences
- Published
- 2026-06-16
- DOI
- https://doi.org/10.3390/medsci14020325
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00